GlassScriptPhysician profile
Matteo Lopiccolo
NPI 1952565897
$1,427.17
in general payments reported to CMS, 2019-2025
14 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.99 · 2022: $289 · 2023: $371 · 2024: $409 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $285.29 | 2022-2025 | Libtayo, Dupixent |
| Abbvie INC. | $219.47 | 2022-2025 | |
| Genzyme Corporation | $179.21 | 2021-2025 | |
| Kerecis Limited | $141.98 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen |
| Lilly USA, LLC | $136.98 | 2022-2023 | Taltz, Olumiant |
| Janssen Biotech, INC. | $88.73 | 2023-2025 | Tremfya |
| Organon LLC | $71.78 | 2024-2025 | |
| Leo Pharma INC. | $66.10 | 2023-2024 | Adbry |
| Ucb, INC. | $54.35 | 2023-2024 | Bimzelx |
| Kyowa Kirin, INC. | $48.04 | 2022-2025 | Poteligeo |
| Incyte Corporation | $46.82 | 2023 | Opzelura |
| Sun Pharmaceutical Industries INC. | $36.89 | 2025 | |
| Organogenesis INC. | $33.95 | 2024 | |
| Arcutis Biotherapeutics, INC. | $17.58 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matteo Lopiccolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.